CTIS2023-508066-15-00进行中（未招募）1 期
18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study
niversity Hospital Maastricht0 个研究点目标入组 10 人开始时间: 2024年3月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Female patient with histopathologically proven ER+ breast cancer., Diagnosed with locally advanced (primary tumor >5 cm and/or presence of axillary lymph node metastases) or recurrent breast cancer, for which 18F-FDG PET/CT or 18F-FDG PET/MRI staging is performed., Willing and able to undergo the study procedures., Has personally provided written informed consent.
排除标准
- •Age <18., Pregnancy., Patients with secondary malignancies., No 18F-FDG PET/CT or 18F-FDG PET/MRI scan., Contra-indications for PET/MRI such as pacemaker, aneurysm clips, metallic device in their body, severe claustrophobia, and severe obesity, Inability to provide informed consent., Chronic inflammatory disease such as rheumatoid arthritis., Patients with severe hepatic or renal impairment (eGFR =45mL/min/1.73m²)
研究者
相似试验
招募中
Unknown
A comparative study of F-18 FBPA-PET and F-18 FDG-PET in head and neck cancerHead and neck cancerJPRN-UMIN000049242Osaka University Graduate School of Medicine85
招募中
2 期
18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study2023-508066-15-01University Hospital Maastricht20
Unknown
不适用
Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast CarcinomaBreast NeoplasmsPositron Emission TomographyFibroblast Activation Protein InhibitorFluorodeoxyglucose F18NCT05339113The National Center of Oncology, Azerbaijan100
已完成
不适用
18F-FDG and 68Ga-FAPI PET/CT in Lung AdenocarcinomaLung Adenocarcinoma18F-FDG68Ga-FAPIPET/CTNCT04588064The First Affiliated Hospital of Xiamen University63
进行中（未招募）
1 期
Comparative study of a specific imaging biomarker, 68Ga-PSMA-11, and the standard imaging protocol with 18F-Fluorocholine in the detection of Recurrence in Prostate Cancer PatientsMedDRA version: 20.0 Level: PT Classification code 10036911 Term: Prostate cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10076506 Term: Castration-resistant prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10036917 Term: Prostate cancer stage I System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10036918 Term: Prostate cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspProstate CancerEUCTR2016-003740-36-PTICNAS Produção Lda.46